Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic

Affiliations

• ¹ Drug Development Department (DITEP) Gustave Roussy-Cancer Campus, Villejuif, France; Université Paris Saclay, Université Paris-Sud, Faculté de Médicine, Le Kremlin Bicêtre, Paris, France; Oncostat U1018, Inserm, Paris-Saclay University, Labeled Ligue Contre le Cancer, Villejuif, France. Electronic address: arnaud.bayle@gustaveroussy.fr.
• ² Drug Development Department (DITEP) Gustave Roussy-Cancer Campus, Villejuif, France.
• ³ Oncostat U1018, Inserm, Paris-Saclay University, Labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif Cedex, France.
• ⁴ Department of Medical Oncology, Gustave Roussy, Villejuif, France.
• ⁵ Université Paris Saclay, Université Paris-Sud, Faculté de Médicine, Le Kremlin Bicêtre, Paris, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
• ⁶ Drug Development Department (DITEP) Gustave Roussy-Cancer Campus, Villejuif, France; Université Paris Saclay, Université Paris-Sud, Faculté de Médicine, Le Kremlin Bicêtre, Paris, France.
• ⁷ Department of Medical Oncology, Gustave Roussy, Villejuif, France; Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.
• ⁸ Drug Development Department (DITEP) Gustave Roussy-Cancer Campus, Villejuif, France; ATIP-Avenir, U981 INSERM, Villejuif, France. Electronic address: sophie.postel-vinay@gustaveroussy.fr.